Roche’s “Brilliant Concept” Fades Amid Doctor Disappointment

The cancer drug Avastin, introduced in 2004, has largely lived up to its billing as an innovative way to attack cancer, along the way generating the most revenue for any cancer drug while being Roche Holding AG’s best-selling product with 6.46 billion Swiss francs ($6.88 billion) in sales last year.
SF Gate